Vnitr Lek 2007, 53(4):391-395

CRP - a marker of a pro-inflammatory state and cardiovascular risk

R. Poledne*, Z. Valenta, J. Pi»ha
Laboratoř pro výzkum aterosklerózy, Pracoviątě experimentální medicíny IKEM Praha, přednosta doc. MUDr. Luděk Červenka, CSc.

The importance of elevated basal levels C-reactive protein (CRP) measured by a highly sensitive test has been known for over 10 years. Increased hsCRP concentration correlates with most of the classical risk factors in cardiovascular disease, however. This seriously complicates the interpretation of the elevated concentration. Concentrations of hsCRP are partly genetically determined and can easily be affected positively by lifestyle changes. These two factors lead us to conclude that the setting of hsCRP should not be used routinely at present in assessing the individual risk of complications for atherosclerosis.

Keywords: cardiovascular disease; risk factors; pro-inflammatory state

Received: April 3, 2007; Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poledne R, Valenta Z, Pi»ha J. CRP - a marker of a pro-inflammatory state and cardiovascular risk. Vnitr Lek. 2007;53(4):391-395.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dvořáková A, Poledne R. Zánětlivé mechanizmy ve vzniku a progresi aterosklerózy. ČLČ 2003; 142: 70-74.
    2. Dvořákova A, Poledne R. The incidence of infectious disease and changes in the mortality of atherosclerosis-related complications in the Czech population over the past two decades. Eur J Epid 2004; 19: 707-710. Go to original source... Go to PubMed...
    3. Hubáček JA, Pi»ha J, ©kodová Z et al. C(-260)→T polymorphysm in the promoter of the CD14 monocyte receptor gene as a risk factor for myocyrdial infarction. Circulation 1999; 99: 3218-3220. Go to original source... Go to PubMed...
    4. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979. Go to original source... Go to PubMed...
    5. Ridker PM, Cushman M, Stampfer MJ et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428. Go to original source... Go to PubMed...
    6. Rao M, Jaber BL, Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Semin Dial 2006; 2: 129-135. Go to original source... Go to PubMed...
    7. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197. Go to original source... Go to PubMed...
    8. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843. Go to original source... Go to PubMed...
    9. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men - results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 1999; 99: 237-242. Go to original source... Go to PubMed...
    10. Castell JV, Gomez-Lechon MJ, David M et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-239. Go to original source... Go to PubMed...
    11. Dvořáková-Lorenzová A, Suchánek P, Havel PJ et al. The Decrease in C-reactive protein concentration after moderate weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism 2006; 55: 359-365. Go to original source... Go to PubMed...
    12. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary Artery disease. Am J Cardiol 2003; 92: 10i-18i. Go to original source... Go to PubMed...
    13. Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis 2003; 169: 279-282. Go to original source... Go to PubMed...
    14. Festa A, D'Agostino RJ, Howard G et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47. Go to original source... Go to PubMed...
    15. Tintera J, Harantová P, Suchánek P et al. Quantification of intra-abdominal fat during controlled weight reduction: assessment using the water-suppressed breath-hold MRI technique. Physiol Res 2004; 53: 229-234. Go to original source...
    16. Staněk V, Lorenzová A, Cífková R et al. The changing spektrum of risk factors for coronary heart disease. Cor Vasa 2007 (v tisku).
    17. Ranjit N, Diez-Roux AV, Shea S et al. Psychosocial factors and inflammation in the multiethnic study of atherosclerosis. Arch Intern Med 2007; 167: 174-181. Go to original source... Go to PubMed...
    18. de Maat MPM, Trion A C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2004; 15: 651-657. Go to original source... Go to PubMed...
    19. Paul A, Yeh ETH, Chan L A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol 2005; 16: 512-517. Go to original source... Go to PubMed...
    20. Trion A, de Maat MP, Jukema JW et al. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005; 25: 1635-1640. Go to original source... Go to PubMed...
    21. Ballantyne CHM, Nambi V Markers of inflammation and their clinical significance. Atherosclerosis Suppl 2005; 6: 21-29. Go to original source... Go to PubMed...
    22. de Ferranti SD, Rifai N C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovascular Patology 2007; 16: 14-21. Go to original source... Go to PubMed...
    23. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397. Go to original source... Go to PubMed...
    24. Reifenberg K, Lehr HA, Baskal D et al. Role of C-reactive protein in atherogenesis: Can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol 2005; 5: 1641-1646. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.